<DOC>
	<DOCNO>NCT00371150</DOCNO>
	<brief_summary>The purpose clinical research study develop observational clinical experience use entecavir participant either Black/African-American race Hispanic ethnicity .</brief_summary>
	<brief_title>Effect Entecavir Blacks/African Americans Hispanics With Chronic Hepatitis B Virus ( HBV ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Chronic HBV infection , either HBeAgpositive ( HBeAbnegative ) HBeAgnegative ( HBeAbpositive ) disease Black/African American Race and/or Hispanic ethnicity Nucleoside/tidenaive Males females â‰¥ 16 year age ( minimum age require give country ) Compensated liver function ALT 1.3 10 x upper limit normal ( ULN ) No Coinfection human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) hepatitis D virus ( HDV ) Exclusion Criteria Women childbearing potential ( WOCBP ) unwilling unable use acceptable method avoid pregnancy entire study period 6 week study medication discontinue Women pregnant breastfeed Women positive pregnancy test enrollment prior study drug administration Evidence decompensated cirrhosis include limited : variceal bleeding ; hepatic encephalopathy ; ascites require management diuretic paracentesis Recent history pancreatitis ( resolution recent pancreatitis must document normal lipase least 12 week prior first dose study medication ) Currently abuse illegal drug alcohol sufficient , investigator 's opinion , prevent adequate compliance study therapy increase risk hepatotoxicity pancreatitis Other serious medical condition might preclude completion study require chronic administration prohibit medication Serum creatinine &gt; 1.5 mg/dL Hemoglobin &lt; 10.0 g/dL Platelet count &lt; 70,000/mm3 Absolute neutrophil count &lt; 1200 cells/mm3 Serum alpha fetoprotein ( AFP ) level &gt; 100 ng/mL . If AFP level 21 100 ng/mL , must repeat . If repeat AFP level 21 100 ng/mL ultrasonography computerize tomography ( CT ) liver perform prior first dose study medication demonstrate focal lesion suggestive carcinoma , subject may dose study Known history allergy nucleoside analogues Any prior therapy Entecavir Any prior concomitant use nucleoside nucleotide analogue antiviral agent activity hepatitis B ( e.g. , ETV , lamivudine ( LVD ) , tenofovir [ TDF ] , emtricitabine ( FTC ) , clevudine , telbivudine [ LdT ] , famciclovir ) , experimental antiHBV antiviral agent Therapy interferon , thymosin alpha immunostimulators within 24 week enrollment ( i.e. , dose ) study Subjects require chronic administration concomitant medication cause immunosuppression associate high rate nephrotoxicity hepatotoxicity , affect renal excretion , enrol study Unable tolerate oral medication Poor peripheral venous access Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious disease ) illness must enrol study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>